Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis

Bhuriya, Rohit; Singh, Mukesh; Molnár, J.; Arora, Rohit; Khosla, Sandeep

doi:10.1016/j.ijcard.2009.11.041

Cited by 45 publications

(28 citation statements)

References 33 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent nationwide register study from The side effects of bisphosphonates include osteonecrosis of the jaw, (35) esophageal irritation, musculoskeletal pain, subtrochanteric femoral stress fractures (alendronate), (36) and atrial fibrillation. (37) According to a recent published secondary analysis using the results of three randomized bisphosphonate trials (n ¼ 14,195), the occurrence of fractures of the subtrochanteric or diaphyseal femur was rare, even in women with osteoporosis who received bisphosphonates for up to 10 years. (38) We can learn much about these side effects, but the riskbenefit balance of bisphosphonates in patients with osteoporosis remains strongly positive.…”

Section: Post-hip Fracture Use Of Osteoporotic Drugs Lower Mortalitymentioning

confidence: 99%

Post–hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland

Nurmi-Lüthje

Sund

Juntunen

et al. 2011

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

We previously found a positive association between calcium plus vitamin D and antiosteoporotic drugs and survival among hip fracture patients. Our aim was to verify this observation using a nationwide database. A retrospective cohort of home-discharged hip fracture patients aged 50 years or older (n ¼ 23,615) was enrolled from the national database. Primary exposure was medical treatment for osteoporosis, and the outcome was all-cause mortality. Cumulative mortalities were calculated using the Kaplan-Meier estimator. The relationship between mortality and medication purchases was modeled using Cox's proportional hazards regression with timedependent covariates for medication use. One in 4 women and 1 in 10 men with a hip fracture were treated for osteoporosis in Finland. Unadjusted 1-year mortality was lower among patients who purchased calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs than among those who did not purchase these medications [hazard ratio (HR) ¼ 0.74, 95% confidence interval (CI) 0.67-0.81]. The difference in unadjusted cumulative mortality remained in favor of the drug users for at least 5 years. Among men, the use of calcium plus vitamin D or vitamin D supplements was associated with lower 1-year mortality even after adjustments for observed confounders (HR ¼ 0.74, 95% CI 0.56-0.97). Among women, the use of antiosteoporotic drugs was associated with lower mortality (HR ¼ 0.79, 95% CI 0.67-0.93). There was a tendency to even better survival in both genders if calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs were used simultaneously, the HR being 0.72 (95% CI 0.50-1.03) in men and 0.62 (95% CI 0.50-0.76) in women. ß

show abstract

Section: Post-hip Fracture Use Of Osteoporotic Drugs Lower Mortalitymentioning

confidence: 99%

Post–hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland

Nurmi-Lüthje

Sund

Juntunen

et al. 2011

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…However, a recent systematic review of the literature precludes any definite conclusions due to the paucity of evidence [13]. Another systematic review that included only clinical trials found evidence of a significantly increased risk of atrial fibrillation associated with bisphosphonate, but clinical trials without information on atrial fibrillation were excluded in this meta-analysis thereby giving rise to substantial limitations [14].…”

Section: Introductionmentioning

confidence: 99%

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Rhee

Lee

et al. 2011

Osteoporos Int

View full text Add to dashboard Cite

show abstract

“…Preoperative management, such as use of ß-blockers, avoidance of angiotensin-converting enzyme inhibitors, and shorter cardiopulmonary bypass and aortic clamp times can reduce incidence of new-onset AF [8]. Bisphosphonate use was associated with a significant increase in the risk of serious AF [9]. Another interesting study tried to examine whether or not exposure to non-steroidal anti-inflammatory drugs (NSAIDs) was a risk factor for AF.…”

Section: To the Editormentioning

confidence: 99%

Hemostatic markers can be pivotal roles of risk factors for new-onset atrial fibrillation

et al. 2013

View full text Add to dashboard Cite

Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis

Cited by 45 publications

References 33 publications

Post–hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland

Post–hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Hemostatic markers can be pivotal roles of risk factors for new-onset atrial fibrillation

Contact Info

Product

Resources

About